BioCentury | Apr 1, 2017
Clinical News

NIH starts Phase II trial of Zika vaccine

...The NIAID expects to complete the trial by 2019. Other clinical Zika vaccine candidates include GLS-5700...
BioCentury | Jan 27, 2017
Clinical News

GLS-5700: Ph I data

...I trial in 40 healthy volunteers showed that 1 and 2 mg doses of intradermal GLS-5700...
...of intradermal GLS-5700 in 160 dengue virus-seropositive adults are expected this year. Inovio is developing GLS-5700...
...NASDAQ:INO), Plymouth Meeting, Pa. GeneOne Life Science Inc. (KSE:011000), Seoul, South Korea Product: GLS-5700 (formerly SynCon Zika DNA vaccine...
BioCentury | Dec 22, 2016
Product R&D

Fever pace for Zika

...Institutions Description Status Nucleic acid-based vaccine GeneOne Life Science Inc. (KSE:011000); Inovio Pharmaceuticals Inc. (NASDAQ:INO) GLS-5700...
...West Nile, dengue and yellow fever viruses. - Mary Romeo This week, Inovio reported that GLS-5700...
...Zika-naïve subjects after one or two vaccinations with low-dose or high-dose vaccine. Inovio is developing GLS-5700...
BioCentury | Sep 5, 2016
Clinical News

SynCon Zika DNA vaccine: Phase I started

...I trial of GLS-5700 in 40 volunteers are expected before year end. Inovio is developing GLS-5700...
...Inc. (KSE:011000), Seoul, South Korea Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: SynCon Zika DNA vaccine ( GLS-5700...
BioCentury | Jun 28, 2016
Politics & Policy

HHS working with Emergent on Zika vaccine

...Science Inc. (KSE:011000) said they plan to start a Phase I study within weeks of GLS-5700...
BioCentury | Jun 27, 2016
Clinical News

SynCon Zika DNA vaccine: Phase I start

...per intradermal dose of GLS-5700 in about 40 healthy volunteers. The companies are developing Inovio’s GLS-5700...
...Inc. (KSE:011000), Seoul, South Korea Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: SynCon Zika DNA vaccine ( GLS-5700...
BioCentury | Jun 21, 2016
Clinical News

Inovio, GeneOne plan clinical study of Zika vaccine

...said they plan to start an open-label Phase I study "in the next weeks" of GLS-5700...
...expect interim data from the dose-ranging study, which is to enroll about 40 healthy volunteers. GLS-5700...
BioCentury | May 23, 2016
Clinical News

GeneOne, Inovio preclinical data

...In non-human primates, 2 doses of GLS-5700 administered either intramuscularly or intradermally led to seroconversion in...
...BioCentury, Feb. 22). Inovio plans to start Phase I testing of the vaccine this year. GLS-5700...
...Inc. (KSE:011000), Seoul, South Korea Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: SynCon Zika DNA vaccine ( GLS-5700...
BioCentury | Feb 22, 2016
Clinical News

GeneOne, Inovio preclinical data

...Inovio said its SynCon Zika DNA vaccine led to seroconversion in all vaccinated mice and generated “robust and broad”...
...Life Science Inc. (KSE:011000), Seoul, South Korea Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: SynCon Zika DNA vaccine...
Items per page:
1 - 9 of 9